Daewoong Pharmaceutical Secures 145.2 Billion Won MENA Export Deal for Diabetes Drug Enblo
Daewoong Pharmaceutical’s proprietary type 2 diabetes treatment, Enblo (active ingredient: enavogliflozin), is set to enter eight major markets in...
Biowatch
Celltrion Secures Historic FDA Interchangeability Status for Truxima
Celltrion announced on the 1st that the U.S. Food and Drug Administration has granted interchangeable status to Truxima (active ingredient:...
Fueling the Future of Biohealth: InterBiz Forum Opens in Jeju With a Record 1,500 Tech Deals
The 24th InterBiz Bio Partnering & Investment Forum 2026, a premier biohealth technology deal-making event, opened...
Dongkook Pharmaceutical Secures 39 Billion Won Latin American Export Deal for BPH Treatment Uresco
Waking up frequently at night to urinate or noticing a weaker urine stream is a common health concern for men as they...
Inha University Hospital Partners with Remedi to Validate Ultra-Compact, AI-Powered X-Ray Models for Frontline Care
Inha University Hospital has signed a memorandum of understanding with Remedi, a medical technology developer...
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer
Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its...
Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs
With wage and collective bargaining talks between Samsung Biologics and its union still unresolved, analysts expect...
Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment
Treatment for inflammatory bowel disease is rapidly moving beyond simple symptom management toward the structural...
Medytox’s Neuramis Clinches China Approval, Paving Way for Dermal Filler Market Entry
Medytox announced on the 25th that China’s National Medical Products Administration has granted product approval for...
Rznomics Secures U.S. Patent for Alzheimer’s RNA Therapy Candidate RZ-003
Rznomics, a biopharmaceutical company specializing in RNA-based gene therapies, announced on the 24th that it has...